You will do really well to read their half yearly, and the yearly prior, and quarterlies; the product and tech is real; it is just a matter of getting partners (bio firms like AccessBio and Lumos) to use the kit.
re up to speed, the share rocketed on perceived 15-20 mill revenue this year ending tomorrow; yet we will do $8 mill max (just looking at quarterlies); so the share dove on unfulfilled (or delayed) sales; where it goes from here depends on revenue, which turns into operational profit, and eventually positive earnings per share. When? If? How much? Mr Market not really convinced yet.
AT1 Price at posting:
18.5¢ Sentiment: Hold Disclosure: Held
